Efficacy of Losartan in the management of Post-Dialysis Euvolemic Hypertension (HELD-Trial): A Single-Blind Randomized Control Trial

• Published in: Scientific reports 2016-12, Vol.6 (1), p.36592-36592, Article 36592
• Main Authors: Aftab, Raja Ahsan, Khan, Amer Hayat, Adnan, Azreen Syazril, Sulaiman, Syed Azhar Syed, Khan, Tahir Mehmood
• Format: Article
• Language: English
• Subjects: 692/4022/1585/104/1586; 692/4022/1950/1544; Adult; Aged; Aged, 80 and over; Antihypertensives; Blood pressure; Blood Pressure - drug effects; Dialysis; Female; Hemodialysis; Humanities and Social Sciences; Humans; Hypertension; Hypertension - drug therapy; Hypertension - etiology; Hypertension - physiopathology; Losartan - administration & dosage; Male; Middle Aged; multidisciplinary; Prospective Studies; Renal Dialysis - adverse effects; Science; Tomatoes
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/srep36592

To assess the effectiveness of losartan 50 mg on post dialysis euvolemic hypertensive patients against standard antihypertensive pharmacotherapy. A multicentre, prospective, randomized, single-blind trial was conducted to assess the effect of losartan 50 mg every other day (EOD), once a morning (OM) among post-dialysis euvolemic hypertensive patients. Covariate-adaptive randomization was used to allocate participants to a standard or treatment arm, and they were followed up for eight weeks. Pre-, intra- and post-dialysis session blood pressure (BP) measurements were recorded along with any adverse events. A total of 88 patients were randomized into standard (n = 44) and treatment arms (n = 44) and were followed for a period of 8 weeks. In the standard group, the mean post-dialysis blood pressure dropped by 0.3 mmHg by the end of the 8 th week. However the treatment arm reported a drop of 2.4 mmHg of BP drop during the 8-week trial period. Analysis suggests that there was a significant difference in blood pressure readings at the end of 8 weeks among patients treated with losartan (P